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Remission of type 2 diabetes mellitus with metabolic surgery is a ﬁeld of active investigation and development. The extraordinary
results obtained in diabetic patients with BMI > 35kg/m2 have led investigators to query if similar results could be achieved in
patientswithBMI<35kg/m2.Afewstudieshavebeenrecentlyconductedtoevaluatethesafety,eﬀectiveness,andcosteﬀectiveness
ofbariatricsurgeryindiabetic patients withBMIBMI <35kg/m2. However, strongerevidence would be required before insurance
coverage is extended for bariatric surgery to all type 2 diabetic patients, in addition to those with BMI ≥ 35kg/m2 for whom
eligibility is already established. In addition, the hormonal and metabolic mechanisms of diabetes remission after gastrointestinal
surgery are yet to be determined. This paper will review the evidence about safety, eﬀectiveness, and cost eﬀectiveness of bariatric
surgery in type 2 diabetes mellitus remission and the potential socioeconomic impact of oﬀering bariatric surgery to diabetic
patients with BMI BMI < 35kg/m2.
1.Introduction
Type 2 Diabetes Mellitus (T2DM) is a major cause of
morbidity and mortality around the world. The prevalence
of T2DM in the US was 8% in 2008 [1]. According to the
American Diabetes Association, the total estimated cost of
diabetes in 2007 was $174 billion [2]. The traditional goal for
medicaltreatmentofT2DMhasbeentodelaytheappearance
of end-organ complications. In contrast, surgical treatment
for T2DM is currently being evaluated as a potential “cure”
for T2DM. Several studies have demonstrated that obese
diabetic patients who undergo bariatric surgery experience
complete T2DM remission, maintaining euglycemia without
medications for more than 10 years [3]. Additionally,
following some gastrointestinal (GI) procedures, T2DM
resolves within days to weeks, long before the occurrence
of major weight loss [4]. Bariatric surgery as a modality
to treat obesity in the US is reserved for patients with
BMI ≥ 35kg/m2 and the presence of serious comorbidities
(T2DM, moderate or severe obstructive sleep apnea (OSA),
pseudotumor cerebri, and severe steatohepatitis), or BMI >
40kg/m2 and minor comorbidities (mild OSA, hypertension
(HTN), insulin resistance, glucose intolerance, dyslipidemia,
impairedqualityoflife,oractivitiesofdailyliving)[5].How-
ever, some recent publications also suggest that conventional
bariatric surgery results in remission of T2DM in patients
with BMI < 35kg/m2 [6, 7]. In addition, novel antidiabetic
GI procedures have been developed by groups outside the
US to treat T2DM patients with BMI < 35kg/m2 [8, 9]. In
view of the growing enthusiasm for surgical interventions to
treat T2DM, the 1st diabetes surgery summit (DSS) was held
in Rome in March 2007 to develop guidelines for the use
of GI surgery to treat T2DM. The DSS position statement
included that a surgical approach may be appropriate as
a nonprimary alternative to treat inadequately controlled
T2DM in suitable surgical candidates with BMI 30–35kg/m2
and that novel GI surgical techniques (duodenal-jejunal
bypass, ileal interposition, sleeve gastrectomy, and endo-
luminal sleeves) should be used only in the context of
IRB-approved trials [10]. The growing interest in oﬀering
surgical therapy to T2DM patients with BMI < 35kg/m2
within the world surgical community has not yet spread
to the US surgical community. A major limitation for the
development of the ﬁeld of metabolic surgery in the US is2 Journal of Obesity
the absence of insurance coverage for bariatric procedures
in T2DM patients with BMI < 35kg/m2. Several studies
have demonstrated that adjustable gastric banding (AGB)
and Roux-en-Y gastric bypass (RYGB) are cost eﬀective at 5-
yearfollowupincomparisontoconventionaltreatment(CT)
for T2DM in patients with BMI ≥ 35kg/m2 [11–14]. One
study has also shown cost eﬀectiveness of bariatric surgery
in patients with T2DM and BMI ≥ 30 and <40kg/m2 [15].
The purpose of this paper is to review the existing literature
about safety, eﬀectiveness, and cost eﬀectiveness of bariatric
surgeryinT2DMremissionandthepotential socioeconomic
impact of oﬀering bariatric surgery to diabetic patients with
BMI < 35kg/m2.
2.MorbidityandMortalityof BariatricSurgery
Trends in mortality in bariatric surgery were reported by
Buchwald et al. [16] in 2007. This systematic review and
meta-analysis included 360 studies for a total of 85,000
patients with a mean BMI of 47.4kg/m2. In contrast to the
popular belief that bariatric surgery is a drastic measure to
treatobesitybecauseofitsassociatedrisks,thisstudydemon-
strates that mortality from laparoscopic RYGB (LRYGB) is
comparable to mortality from laparoscopic cholecystectomy,
which is considered to be a safe operation by the general
public. Mortality rates from LRYGB in this study were 0.16%
within 30 days and 0.09% from 30 days to 2 years. Similarly,
a 30-day postoperative mortality of 0.3% after RYGB or
laparoscopic AGB (LAGB) was reported by the Longitudinal
Assessment of Bariatric Surgery (LABS) Consortium, a 10-
center prospective trial involving 4776 patients undergoing
bariatric surgery. This study also reported a composite end
pointofdeathorseriouscomplicationof4.1%within30days
after surgery [17]. Gastric bypass surgery has been associated
with decreased long-term total mortality in severely obese
patients, as demonstrated by Adams et al. [18] in 2007. This
retrospectivecohortstudycomparedthelong-termmortality
of 7925 patients who underwent gastric bypass surgery
matched for age, sex, and BMI to severely obese control
subjects who applied for driver’s licenses, using the National
Death Index. During a mean followup of 7.1 years, adjusted
long-term mortality from any cause in the surgery group
decreased by 40%, as compared with that in the control
group (37.6 versus 57.1 deaths per 10,000 person-years,
P<. 001); cause-speciﬁc mortality in the surgery group
decreased by 56% for coronary artery disease (2.6 versus 5.9
per 10,000 person-years, P = .006), by 92% for diabetes
(0.4 versus 3.4 per 10,000 person-years, P = .005) and by
60% for cancer (5.5 versus 13.3 per 10,000 person-years,
P<. 001) However, rates of death not caused by disease,
suchasaccidentsandsuicide,were58%higherinthesurgery
group than in the control group (11.1 versus 6.4 per 10,000
person-years, P = .04). Sj¨ ostr¨ om et al. [19] also reported
a survival beneﬁt of bariatric surgery over conventional
treatment for obesity. This prospective controlled study
compared 2010 patients who underwent bariatric surgery
(AGB:376;RYGB:265;verticalbandedgastroplasty:1369)to
2037patientswhoreceivedconventionaltreatment(matched
control group). The unadjusted overall hazard ratio was 0.76
in the surgery group (P = .04), as compared with the
control group, and the hazard ratio adjusted for sex, age, and
risk factors was 0.71 (P = .01). The most common causes
of death were myocardial infarction and cancer. Perioper-
ative complications were experienced by 13% of patients,
which included bleeding (0.9%), thromboembolic events
(0.8%), wound complications (1.8%), abdominal infection
(2.1%), pulmonary symptoms (6.2%), and miscellaneous
(4.8%). Postoperative complications requiring reoperation
were experienced by 2.2%.
3. Effectivenessof BariatricSurgery in
T2DM Remission in Patientswith T2DM
andBMI ≥ 35kg/m2
The bariatric literature has consistently demonstrated a
signiﬁcant eﬀect of bariatric surgery in T2DM remission
in patients with BMI ≥ 35kg/m2. T2DM resolution or
remission has usually been deﬁned as HbA1C values ranging
from<6%to<7%intheabsenceofantidiabeticmedications.
The prospective, controlled Swedish Obese Subjects Study
by Sj¨ ostr¨ om et al. [20] reported a signiﬁcant diﬀerence in
the prevalence of diabetes between the surgery group and
the conventional treatment group (2 years: 1% versus 8%,
P<. 001; 10 years: 7% versus 24%, P<. 001). Participants
who underwent surgery were more likely to recover from
diabetes (2 years: 72% versus 21%, P<. 001; 10 years:
36% versus 13%, P<. 001). A systematic review and meta-
analysis of bariatric surgery by Buchwald et al. [3] included
136 studies for a total of 22,094 patients; mean baseline
BMI was 46.9kg/m2 (32.3–68.8). The studies that reported
resolution of T2DM included a total of 1846 patients.
Diabetes resolution rates were 98.9% after biliopancreatic
diversion (BPD), 83.7% after RYGB and 47.9% after AGB.
Another systematic review by Levy et al. [21] conﬁrmed that
bariatric surgery was highly eﬀective in obtaining weight
reduction in morbidly obese patients of up to 60% of the
excess weight, along with resolution of preoperative diabetes
in more than 75% of the cases.
4. Cost Effectivenessof BariatricSurgeryin
Patients withT2DM andBMI ≥ 35kg/m2
Ackroyd et al. [11] established a payer-perspective cost
eﬀe c t i v e n e s sa n db u d g e ti m p a c t( B I )m o d e lo fA G Ba n d
RYGB versus CT in patients with BMI ≥ 35kg/m2 and
T2DM in Germany, UK, and France (Table 1). The base
case time scope was 5 years, and the annual discount rate
for utilities and costs was 3.5%. In Germany and France,
b o t hR Y G B Pa n dA G By i e l d e dac o s td e c r e a s ea n dw e r e
thus dominant in terms of incremental cost-eﬀectiveness
ratio (ICER) compared to CT. In the UK, RYGBP and AGB
yielded a cost increase but were cost-eﬀective. The authors
concluded that, in patients with T2DM and BMI ≥35kg/m2,
AGB and RYGBP are eﬀective at 5-year followup in cost-
saving in Germany and France and are cost eﬀective in the
UK with a moderate BI versus CT. Anselmino et al. [12]
replicated this model in Austria, Italy, and Spain. In AustriaJournal of Obesity 3
Table 1: Cumulative cost per patient over 5 years including cost of therapy, cost of complications, and cost of prevalent T2DM [11].
Study Conventional therapy Laparoscopic adjustable gastric banding Laparoscopic gastric bypass
Germany C17197 C13610 C12166
France C19276 C14796 C13399
United Kingdom £7083 £9072 £9121
Table 2: Summary results for the base-case analysis [13].
35-year time horizon Bariatric surgery Medical management Diﬀerence
Life expectancy, y 11.536 (0.424) 10.870 (0.187) +0.6666 (0.460)
Quality-adjusted life expectancy, y 6.782 (0.479) 5.883 (0.105) +0.8999 (0.493)
Total costs (2007, dollars) 83,482 (3191) 63,722 (2296) +19,760 (3861)
Management 9117 11,621 −2504
Cardiovascular disease 34,811 37,824 −3013
Renal 3592 4539 −947
Eye 3769 3963 −194
Ulcer/neuropathy/amputation 5915 5776 +139
Surgery 23,131 0 +23,131
Incremental cost per life-year gained (2007, dollars) — — 29,676
Incremental cost per QALY gained (2007, dollars) — — 21,973
and Italy, both AGB and RYGBP are cost saving and are
thus dominant in terms of ICER compared to CT. In Spain,
AGB and RYGBP yield a moderate cost increase but are cost
eﬀective, assuming a willingness to-pay threshold of 30,000
euro per quality adjusted life year (QALY). Under worst-
case analysis, AGB and RYGBP remain cost saving or around
breakeven in Austria and Italy and remain cost eﬀective in
Spain.
A similar study was conducted in the US by Ikramuddin
et al. [13]. The analysis showed that compared with medical
management, RYGB surgery for obese diabetic patients has a
costeﬀectivenessratioof$22,000perQALYgained(Table 2).
The authors concluded that, in the US, RYGB surgery is
cost-eﬀective from a payer’s perspective. From a third-party
payer’s perspective, Cr´ emieux et al. [14] evaluated the return
on investment for bariatric surgery in the United States.
Morbidly obese patients aged 18 years or older were iden-
tiﬁed in an employer claims database of more than 5 million
beneﬁciaries. Each of the 3651 patients who underwent
bariatric surgery during this period was matched to a control
subject who was morbidly obese and never underwent
bariatric surgery. Total healthcare costs for bariatric surgery
patientsandtheircontrolswererecordedfor6monthsbefore
surgery through the end of their continuous enrollment. The
study suggested that the total cost of laparoscopic bariatric
surgery is fully recovered after 25 months. These returns
on investment result from reductions in prescription drug
costs, physician visit costs, and hospital costs (including
emergency department visits and inpatient and outpatient
visits). The reduced costs are associated with multiple major
diagnosis categories, including diabetes mellitus, coronary
artery disease, hypertension, and sleep apnea. Similarly, a
review of 15 years of experience in a French university
hospital reported that bariatric surgery is cost eﬀective after
3.5 years [22].
5. Effectivenessof BariatricSurgery inT2DM
Remission in Patients with BMI < 35kg/m2
Recent publications suggest that the beneﬁcial eﬀects of
bariatric surgery in type 2 diabetic patients are not limited to
patients with BMI ≥ 35kg/m2.O ’ B r i e ne ta l .[ 23]c o m p l e t e d
a randomized clinical trial that included 80 adults with BMI
between 30kg/m2 and 35kg/m2. They reported a signiﬁcant
resolution of the metabolic syndrome in patients undergoing
laparoscopic adjustable gastric banding. Patients in this
study were assigned to a program of very-low-calorie diets,
pharmacotherapy, and lifestyle change for 24 months (non-
surgical group) or to placement of a laparoscopic adjustable
gastric band. The metabolic syndrome was initially present
in 38% of patients in each group and was present in 24%
of nonsurgical patients and 3% of surgical patients at the
completion of the study (P<. 002). A second nonblinded
randomized controlled trial was conducted by Dixon et
al. [24] from December 2002 through December 2006,
which included 60 obese patients with BMI >30 and <40
recently diagnosed with type 2 diabetes. CT reﬂected the
best available medical management including consultation
with a diabetes educator every 6 weeks, medical therapies
as determined by an experienced endocrinologist specialized
in diabetes, and lifestyle modiﬁcation programs. In addition
to all aspects of CT, surgical therapy involved the placement4 Journal of Obesity
of a LAGB. Remission of T2DM (fasting glucose level
<126mg/dL and HbA1C < 6.2% while taking no glycemic
therapy) was observed in 73% of patients in the surgical
group and in 13% of patients in the conventional therapy
group. Remission of T2DM was related to weight loss and
lower baseline HbA1C.
Cohen et al. [25] also demonstrated that obese patients
with a BMI of <35kg/m2 and severe comorbidities can
beneﬁt from LRYGB. A total of 37 patients (mean BMI
32.5kg/m2) who had tried to lose weight with no success and
hadbeenundergoingclinicaltreatmentwithnoresolutionor
improvementoftheirlife-threateningcomorbidities(T2DM,
HTN, lipid disorder, GERD, and sleep apnea) underwent
LRYGB. After extensive explanation and documentation,
the Brazilian insurance companies approved the procedure
in 3 cases, and international (nonAmerican) insurance
companies approved the procedure in 4 cases. The followup
range was 6–48 months. The mean excess weight loss
was 81%. Thirty-six patients had total remission of their
comorbidities. One patient still had mild hypertension, but
with a reduction in the number of antihypertensive drugs
used. No surgery-related complications were reported.
Remission of T2DM in patients with BMI < 35kg/m2
after LRYGB was also published by Lee et al. [26]. This
was a retrospective study of prospectively collected data
that included 201 patients with impaired fasting glucose or
T2DM. Among the 201 patients, 44 (21.9%) had BMI <
35kg/m2 and 157 (78.1%) had BMI ≥ 35kg/m2.O n ey e a r
after surgery, fasting plasma glucose returned to normal
in 89.5% of BMI < 35kg/m2 T2DM and 98.5% of BMI
≥ 35kg/m2 patients (P = .087). The treatment goal of
T2DM (HbA1C < 7.0%, LDL < 150mg/dl, and triglyceride
<150mg/dl) was met in 76.5% of BMI < 35kg/m2 and
92.4% of BMI ≥ 35kg/m2 patients (P = .059). Major
perioperative complications occurred in 4.5% of patients
with BMI < 35kg/m2 and no perioperative mortality. The
authors concluded that despite a slightly lower response
rate of T2DM treatment, patients with include BMI < 35
kg/m2 still had an acceptable T2DM resolution, and this
treatment option can be oﬀered to this group of patients.
A recent study demonstrated T2DM remission and reduced
cardiovascular risk after gastric bypass in Asian Indians with
BMI < 35kg/m2. A total of 15 consecutive patients with
T2DM and a BMI of 22–35kg/m2 underwent RYGB. The
data were prospectively collected before surgery and at 1,
3, 6, and 9 months postoperatively. The BMI decreased
postoperatively by 20%, from 28.9 ± 4.0kg/m 2 to 23.0 ±
3.6kg/m 2 (P<. 001). All antidiabetic medications were
discontinuedby1monthaftersurgeryin80%ofthesubjects.
At 3 months and thereafter, 100% were euglycemic and
no longer requiring diabetes medication. The fasting blood
glucose level decreased from 233 ± 87mg/dL to 89 ±
12mg/dL (P<. 001), and the HbA1C decreased from
10.1% ± 2.0% to 6.1% ± 0.6% (P<. 001). Their waist
circumference, presence of dyslipidemia, and hypertension
improved signiﬁcantly. The predicted 10-year cardiovascular
disease risk (calculated using the United Kingdom Prospec-
tive Diabetes Study equations) decreased substantially for
fatal and nonfatal coronary heart disease and stroke. No
mortality, major surgical morbidity, or excessive weight loss
occurred [27].
6. Cost Effectivenessof BariatricSurgeryin
Patients withT2DM andBMI< 35kg/m2
Cost eﬀectiveness of surgically induced weight loss for the
management of T2DM has also been demonstrated for
patients with BMI >30 and <40kg/m2. Keating et al. [15]
published the within-trial cost eﬃcacy of surgical therapy
relative to CT for achieving remission of recently diagnosed
T2DM in class I and II obese patients. The eﬃcacy results
were derived from a 2-year randomized controlled trial
conducted by Dixon et al. [24]. Trial intervention costs
includedLAGBsurgery,mitigationofsurgicalcomplications,
outpatient medical consultation, pathology, medical investi-
gations, weight loss assisted therapies, and medication. Dur-
ing the ﬁrst 6 months of the trial, mean intervention costs
per patient were approximately sevenfold greater for surgical
patients than for CT patients. The diﬀerence between costs
in each intervention group decreased with each subsequent
6-month period until the last 6 months of the trial, when
intervention costs were equivalent in both groups. The ICER
forsurgicaltherapy(relativetoCT,16,600Australiandollars)
was lower than the comparable ICER for CT (relative to
no intervention, 25,500 Australian dollars). Modeling cost
eﬀectiveness over a longer time period, Keating et al. [28]
concluded that after 10 years the return on investment of
surgical therapy is fully recovered through savings in health
care costs to treat T2DM in the surgical group.
7. Discussion
A signiﬁcant existing body of literature has proven that
bariatric surgery is safe, eﬀective, and cost eﬀective as a
treatment for T2DM in patients with BMI ≥ 35kg/m2.A
rapidly growing body of literature has demonstrated that
bariatric surgery is also safe, eﬀective and cost-eﬀective
as a treatment for T2DM in patients with BMI > 30
and <35kg/m2.H o w e v e r ,m o s td a t ac o l l e c t i o no nw e i g h t
loss surgery has relied on administrative data sets, single-
institution studies, and other sources that are not weight loss
surgery speciﬁc. The results from weight loss surgery speciﬁc
databases, which have been implemented since 2004 (i.e.,
NIH-sponsored longitudinal assessment of bariatric surgery
consortium, the ACS-Bariatric Surgery Center Network, and
the ASMBS/SRC Centers of Excellence Program), could
identify areas for improvement and optimize outcomes and
patient care [29].
There is still controversy in the US health system about
extending coverage for bariatric surgery to all obese patients
with diabetes, in addition to those with BMI ≥ 35kg/m2 for
whom eligibility is already established. This approach would
result in immediate costs of several hundred billion dollars.
Thereisconcernthatsuchexpenditureswouldredirectscarce
resources away from prevention eﬀorts [30]. Although the
studies quoted above refute this argument, opponents to
expanding metabolic surgery argue that at least one recent
studysuggeststhatmaintenanceofweightlossovertimemayJournal of Obesity 5
benobetterinsurgicalpatientsthaninthosewholostweight
without surgery [31]. Weight regain may be associated with
deceleration in the rate of recovery from comorbidities after
bariatric surgery [20].
It is important to promote funding for projects that
study the safety, eﬀectiveness, and cost eﬀectiveness of
metabolic surgery in T2DM patients. The Surgical Therapy
and Medications Potentially Eradicate Diabetes Eﬃciently
(STAMPEDE) trial was designed to evaluate the eﬃcacy
of two bariatric surgery procedures (laparoscopic sleeve
gastrectomy and RYGB) in comparison to advanced med-
ical therapy in patients with T2DM with modest obesity
with BMI of 27–42kg/m2. This single site, prospective,
randomized controlled trial will enroll 150 subjects who
will be followed. The primary end point will be the rate of
biochemical resolution of T2DM at 1 year as measured by
HbA1c < 6%. The safety and adverse event rates will also
be compared between the three arms of the study [32]. The
creation and development of similar parallel trials would
help to validate the results derived from STAMPEDE.
It is also important to promote funding for projects
that investigate the hormonal and metabolic mechanisms of
diabetes remission after gastrointestinal surgery. It appears
that other mechanisms besides weight loss contribute to the
higher rates of T2DM remission after RYGB in comparison
with AGB [33]. Potential mechanisms underlying the direct
antidiabetic impact of RYGB include enhanced nutrient
stimulation of lower intestinal hormones (e.g., glucagon-
like peptide-1), altered physiology from excluding ingested
nutrients from the upper intestine, compromised ghrelin
secretion, modulations of intestinal nutrient sensing, and
regulation of insulin sensitivity, and other changes yet to
be fully characterized [34]. Elucidation of the antidiabetic
mechanisms of RYGB may help develop more potent and
eﬃcacious drugs in the future treatment of T2DM.
Although cost eﬀectiveness of bariatric surgery in
patients with T2DM and BMI < 35kg/m2 have been
reported in at least 2 well-conducted studies, more good
quality evidence is required before extending coverage for
all T2DM patients. It is unclear if all T2DM would be
potential candidates for metabolic surgery or if only patients
that meet certain criteria (e.g., duration of T2DM, BMI,
established cardiovascular disease, insulin dependency, C-
peptide levels, etc.) would beneﬁt while others would not.
ThesocioeconomicimpactofobtainingT2DMremissionvia
metabolic surgery is yet to be determined and should be an
area of active investigation.
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